Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Melatonin on Clock Genes in Parkinson's Disease
NCT04287543Phase 3Withdrawn
- Sponsor
- Instituto Mexicano del Seguro Social
- Start
- May 2021
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Mucomel in Parkinson's disease (PD), sponsored by Instituto Mexicano del Seguro Social. Planned start May 2021; status: withdrawn.
02
Drugs
Mucomel
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT04287543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04287543.